Medical Imaging case studies
Learn how we use imaging to determine patient safety, treatment efficacy, and disease progression
Our end-to-end imaging solutions streamline acquisition, ensure consistency across sites.
We help sponsors minimise trial delays, enhance decision-making, and meet stringent regulatory requirements with robust, data backed evidence
Maximising data capture in obesity trials
A global Phase 2/3 obesity trial leveraged a scalable DXA imaging strategy to overcome equipment limitations and eliminate ‘silent attrition,’ ensuring complete visceral fat data capture across a diverse, multi‑site network.
Imaging process boosts efficiency in oncology device trial
A prominent medical device company was conducting a feasibility study for a device to improve accurate identification of peripheral pulmonary nodules in high risk adult patients. Quality imaging data from multiple sources was critical to the study’s success and ICON helped manage the imaging data for each participant.
Overcoming challenges and exceeding recruitment timeline
ICON was awarded a study in an adult patient population with Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare indication. Despite complex study logistics ICON’s proactive site and patient support strategy enabled recruitment to be completed ahead of schedule.
High-volume medical imaging to support a MASH clinical trial
A pivotal phase 3 randomised, double-blind study to improve MASH and reduce progression to cirrhosis and/or hepatic decompensation, with high volumes of scans across two imaging modalities.
Phase 3 Multiple Myeloma study
A large-pharma sponsor was looking for a medical imaging partner to support a four-year, phase 3 Multiple Myeloma study. This trial included 600 patients and 200 sites and required expedited start-up and turnaround times.
Phase 3 unresectable biliary tract carcinoma study
A large pharmaceutical sponsor required an accelerated medical imaging data delivery for regulatory submission on a phase 3 advanced and/or unresectable biliary tract carcinoma study that spanned 277 sites with 1,115 patients.